EPA and DHA Fatty Acids Induce a Remodeling of Tumor Vasculature and Potentiate Docetaxel Activity
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
n-3 long chain Polyunsaturated Fatty Acids (n-3 LCPUFA) have been shown to improve the efficacy of conventional chemotherapies used for breast cancer treatment. In addition to their reported ability to increase the chemosensitivity of cancer cells, we hypothesized that n-3 LCPUFA could induce a remodeling of the vascular network in mammary tumors. A contrast-enhanced ultrasound method was used to monitor the vascular architecture during docetaxel treatment of mammary tumors in rats fed either a control or an n-3 LCPUFA-enriched diet (docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA)). The vascular network was remodeled in favor of smaller vessels (microvascularization), which represented 54% of the vasculature in n-3 LCPUFA tumors but only 26% in control tumors after 2 weeks of chemotherapy. Importantly, vascularization changes occurred both before and during docetaxel treatment. The density of smaller vessels quantified before chemotherapy was correlated with improved tumor size reduction by docetaxel treatment. Furthermore, transcript levels of the angiogenesis-specific genes epiregulin and amphiregulin were reduced by ~4.5- and twofold in tumors obtained from rats fed an n-3 LCPUFA-enriched diet compared to those of rats fed a control diet, respectively. Their expression levels were negatively correlated with tumor regression after chemotherapy. Taken together, this preclinical data strengthen the potential usefulness of n-3 LCPUFA as a complementary clinical strategy to improve drug efficiency via remodeling of the tumor vasculature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EPA and DHA also have antitumoral and anticancer properties.”
From Microalgae n-3 PUFAs Production and Use in Food and Feed Industries (2021) · cites this paper as [57]
In the citing paper
“Indeed, EPA and DHA can improve drug delivery by modifying the tumor vasculature with architectural remodeling [57], and present antiangiogenic activities [58,59].”
From Microalgae n-3 PUFAs Production and Use in Food and Feed Industries (2021) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 2×
“Vessels become smaller in diameter, less tortuous and are more efficient at delivering oxygen, nutrients, and drugs [2,3].”
BackgroundMolecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529 · cited 1×
“Unlike what is observed in a normal vascular network, tumor vessels have been described as vasodilated and hyperpermeable [13,14].”
BackgroundHigh Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222 · cited 1×
“These alterations can lead to increased interstitial fluid pressure and prevent adequate drug delivery [2,15].”
BackgroundPrinciples and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675 · cited 1×
“During vessel normalization, the architecture of the vasculature is largely restored, in a process that reduces the diameter of microvessels and prunes the most immature vasculature [21].”
BackgroundTong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189 · cited 3×
“Vessels become smaller in diameter, less tortuous and are more efficient at delivering oxygen, nutrients, and drugs [2,3].”
BackgroundKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170 · cited 1×
“This effect creates a window of opportunity during which various concomitantly administered therapies are likely to be most effective [22,23].”
BackgroundCellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781 · cited 1×
“Unlike what is observed in a normal vascular network, tumor vessels have been described as vasodilated and hyperpermeable [13,14].”
BackgroundTumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 691 · cited 2×
“This type of vasculature allows the efficient delivery of cytotoxic agents into tumors and enhances chemotherapy efficacy [1,3].”
BackgroundConnor, K. M., SanGiovanni, J. P., Lofqvist, C., Aderman, C. M., Chen, J., Higuchi, A., Hong, S., Pravda, E. A., Majchrzak, S., Carper, D., et al. (2007) · Nature Medicine · doi:10.1038/nm1591 · Cited by 688
Polyunsaturated fatty acids and inflammation
Calder, P. C. (2006) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2006.05.012 · Cited by 638
Jacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.-L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3744 · Cited by 368 · cited 1×
“These two effectors are also clinically relevant since their mRNA levels in primary tumors can predict the outcome of metastatic colorectal cancer [35].”
Backgroundn -3 Fatty acids, inflammation and immunity: new mechanisms to explain old actions
Calder, P. C. (2013) · Proceedings of the Nutrition Society · doi:10.1017/s0029665113001031 · Cited by 364
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer
Cockbain, A. J., Toogood, G. J., & Hull, M. A. (2012) · Gut · doi:10.1136/gut.2010.233718 · Cited by 305 · cited 1×
“The present preclinical study strengthens the findings of three previously published Phase II clinical trial using n-3 LCPUFA for patients treated for breast, lung, or colon cancers [7,41,42].”
ResultEpoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis
Zhang, G., Panigrahy, D., Mahakian, L. M., Yang, J., Liu, J.-Y., Stephen Lee, K. S., Wettersten, H. I., Ulu, A., Hu, X., Tam, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304321110 · Cited by 293
SCHNEIDER, M. (1999) · Echocardiography · doi:10.1111/j.1540-8175.1999.tb00144.x · Cited by 264
The multiple roles of amphiregulin in human cancer
Busser, B., Sancey, L., Brambilla, E., Coll, J.-L., & Hurbin, A. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.05.003 · Cited by 253 · cited 1×
“The pro-oncogenic activities of AREG and EREG have been examined in previous studies of lung, breast, colorectal, and prostate carcinoma [31,32].”
BackgroundCalviello, G., Di Nicuolo, F., Gragnoli, S., Piccioni, E., Serini, S., Maggiano, N., Tringali, G., Navarra, P., Ranelletti, F. O., & Palozza, P. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh265 · Cited by 244
Murphy, R. A., Mourtzakis, M., Chu, Q. S. C., Baracos, V. E., Reiman, T., & Mazurak, V. C. (2011) · Cancer · doi:10.1002/cncr.25933 · Cited by 221
Hannafon, B. N., Carpenter, K. J., Berry, W. L., Janknecht, R., Dooley, W. C., & Ding, W.-Q. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0400-7 · Cited by 218 · cited 1×
“Other anti-angiogenic effects of DHA have been reported, and they may be mediated through secretion of exosome and their microRNA content [30].”
BackgroundEpiregulin: Roles in normal physiology and cancer
Riese, D. J., & Cullum, R. L. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.03.005 · Cited by 192 · cited 2×
“The pro-oncogenic activities of AREG and EREG have been examined in previous studies of lung, breast, colorectal, and prostate carcinoma [31,32].”
BackgroundResultFatty acids and breast cancer: Sensitization to treatments and prevention of metastatic re-growth
Bougnoux, P., Hajjaji, N., Maheo, K., Couet, C., & Chevalier, S. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.08.003 · Cited by 164 · cited 1×
“The present preclinical study strengthens the findings of three previously published Phase II clinical trial using n-3 LCPUFA for patients treated for breast, lung, or colon cancers [7,41,42].”
ResultSelf-citationHernández‐Vargas, H., Palacios, J., & Moreno‐Bueno, G. (2006) · Oncogene · doi:10.1038/sj.onc.1210102 · Cited by 155 · cited 1×
“In two pre-clinical studies, AREG/EREG were not identified as regulated targets by docetaxel treatment [36,37].”
BackgroundBiondo, P. D., Brindley, D. N., Sawyer, M. B., & Field, C. J. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2008.02.003 · Cited by 152
Modulation of angiogenesis by ω-3 polyunsaturated fatty acids is mediated by cyclooxygenases
Szymczak, M., Murray, M., & Petrovic, N. (2008) · Blood · doi:10.1182/blood-2007-08-109934 · Cited by 123
Benefits of Vascular Normalization Are Dose and Time Dependent—Letter
Huang, Y., Stylianopoulos, T., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1989 · Cited by 110
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
Claes, A., Wesseling, P., Jeuken, J., Maass, C., Heerschap, A., & Leenders, W. P. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0552 · Cited by 105
Eckstein, N., Servan, K., Girard, L., Cai, D., von Jonquieres, G., Jaehde, U., Kassack, M. U., Gazdar, A. F., Minna, J. D., & Royer, H.-D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706287200 · Cited by 102
Yamagata, K. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0514-6 · Cited by 101
Rose, D. P., & Connolly, J. M. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.5.1011 · Cited by 95 · cited 1×
“With others, we have previously reported that n-3 LCPUFA displayed anti-angiogenic properties in rodent tumors [8,9] or in cultured endothelial cells [24,25].”
BackgroundTinhofer, I., Klinghammer, K. F., Weichert, W., Knödler, M., Stenzinger, A., Gauler, T. C., Budach, V., & Keilholz, U. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3338 · Cited by 93 · cited 1×
“However, AREG expression levels have been associated with disease progression of breast cancer or head and neck squamous cell carcinoma in patients receiving a combination treatment of anti-EGFRs and docetaxel [38,39].”
BackgroundTsuji, M., Murota, S.-I., & Morita, I. (2003) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(03)00025-5 · Cited by 93 · cited 2×
“With others, we have previously reported that n-3 LCPUFA displayed anti-angiogenic properties in rodent tumors [8,9] or in cultured endothelial cells [24,25].”
BackgroundCalviello, G., Serini, S., Piccioni, E., & Pessina, G. (2009) · Nutrition and Cancer · doi:10.1080/01635580802582777 · Cited by 88
Colas, S., Mahéo, K., Denis, F., Goupille, C., Hoinard, C., Champéroux, P., Tranquart, F., & Bougnoux, P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0386 · Cited by 79 · cited 2×
“We previously reported that a reduction in the tumor vascularization during n-3 LCPUFA supplementation is accompanied by an enhancement of tumor sensitivity to anthracyclines or taxanes [8,12].”
BackgroundSelf-citationAngiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy
Weiss, A., Bonvin, D., Berndsen, R. H., Scherrer, E., Wong, T. J., Dyson, P. J., Griffioen, A. W., & Nowak-Sliwinska, P. M. (2015) · Scientific Reports · doi:10.1038/srep08990 · Cited by 77
Farooqui, M., Bohrer, L. R., Brady, N. J., Chuntova, P., Kemp, S. E., Wardwell, C. T., Nelson, A., & Schwertfeger, K. L. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0408-z · Cited by 41
Chatterjee, S., Wieczorek, C. M., Schöttle, J., Siobal, M., Hinze, Y., Franz, T., Florin, A., Adamczak, J. M., Heukamp, L. C., Neumaier, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2986 · Cited by 39
Kim, J., Kim, D. K., Min, A., Lee, K.-H., Nam, H.-J., Kim, J. H., Kim, J.-S., Kim, T., Im, S., & Park, I. A. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2012-4 · Cited by 38 · cited 1×
“However, AREG expression levels have been associated with disease progression of breast cancer or head and neck squamous cell carcinoma in patients receiving a combination treatment of anti-EGFRs and docetaxel [38,39].”
BackgroundKoyama, S., Matsunaga, S., Imanishi, M., Maekawa, Y., Kitano, H., Takeuchi, H., & Tomita, S. (2017) · Scientific Reports · doi:10.1038/srep45621 · Cited by 31 · cited 1×
“This effect creates a window of opportunity during which various concomitantly administered therapies are likely to be most effective [22,23].”
BackgroundBroillet, A., Hantson, J., Rüegg, C., Messager, T., & Schneider, M. (2005) · Academic Radiology · doi:10.1016/j.acra.2005.02.021 · Cited by 29
Kornfeld, S., Goupille, C., Vibet, S., Chevalier, S., Pinet, A., Lebeau, J., Tranquart, F., Bougnoux, P., Martel, E., Maurin, A., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr274 · Cited by 27 · cited 6×
“An n-3 LCPUFA diet can alter the tumor vasculature towards an increase in its functional efficacy (decreased interstitial fluid pressure and increased dye perfusion) [12].”
BackgroundResultSelf-citationAnti-Angiogenic Effects of Conjugated Docosahexaenoic Acidin Vitroandin Vivo
Tsuzuki, T., Shibata, A., Kawakami, Y., NAKAGAYA, K., & Miyazawa, T. (2007) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.70114 · Cited by 17 · cited 1×
“With others, we have previously reported that n-3 LCPUFA displayed anti-angiogenic properties in rodent tumors [8,9] or in cultured endothelial cells [24,25].”
BackgroundNon-invasive quantification of tumor vascular architecture during docetaxel-chemotherapy
Mahéo, K., Chevalier, S., Vibet, S., Bougnoux, P., Richard, S., Sérrière, S., Bleuzen, A., Tranquart, F., & Goupille, C. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2015-7 · Cited by 16 · cited 4×
“Importantly, we have previously validated this CEUS method by standard immunohistological analysis [4].”
MethodSelf-citationNagai, M. A. (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000187 · Cited by 11 · cited 1×
“In two pre-clinical studies, AREG/EREG were not identified as regulated targets by docetaxel treatment [36,37].”
Background
Cited by
Microalgae n-3 PUFAs Production and Use in Food and Feed Industries
Remize, M., Brunel, Y., Silva, J. L., Berthon, J.-Y., & Filaire, E. (2021) · Marine Drugs · doi:10.3390/md19020113 · Cited by 214
“Indeed, EPA and DHA can improve drug delivery by modifying the tumor vasculature with architectural remodeling [57], and present antiangiogenic activities [58,59].”
BackgroundNutraceuticals in the Mediterranean Diet: Potential Avenues for Breast Cancer Treatment
Augimeri, G., Montalto, F. I., Giordano, C., Barone, I., Lanzino, M., Catalano, S., Andò, S., Amicis, F. D., & Bonofiglio, D. (2021) · Nutrients · doi:10.3390/nu13082557 · Cited by 63
“Specifically, EPA and DHA potentiate docetaxel activity in remodeling tumor vasculature of mammary tumors [180], opening a window of opportunity in the clinical strategy for breast cancer patients.”
BackgroundConte, C., Longobardi, G., Barbieri, A., Palma, G., Luciano, A., Poggetto, G. D., Avitabile, C., Pecoraro, A., Russo, A., Russo, G., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122618 · Cited by 35
Theinel, M. H., Nucci, M. P., Alves, A. H., Dias, O. F. M., Mamani, J. B., Garrigós, M. M., Oliveira, F. A., Rego, G. N. A., Valle, N. M. E., Cianciarullo, G., et al. (2023) · Nutrients · doi:10.3390/nu15061310 · Cited by 42
“[48] 2020 Induction by drug NMU drug Rats Sprague-Dawley Wildtype F 6 Torres-Adorno et al.”
BackgroundMethodInfluentialFodil, M., Blanckaert, V. D., Ulmann, L., Mimouni, V., & Chénais, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137936 · Cited by 28
“In addition, in a similar model of a chemically-induced mammary tumor, DHA was shown to induce a microvascularization before and during docetaxel treatment, suggesting the potential usefulness of n-3 LC-PUFAs as an adjuvant strategy to enhance common anticancer drug efficiency [62].”
Background
Metadata
- Authors
- Goupille, C., Vibet, S., Frank, P. G., & Mahéo, K.
- Affiliations
- Université de Tours (FR)
- Corresponding author
- Mahéo, Karine
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-07-14
- Volume
- 21
- Issue
- 14
- Pages
- 4965
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7404030
- OpenAlex
- W3042508855
- Cited by
- 17
- References
- 45
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 5 · 2021: 3
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Ligue Contre le Cancer
- Université François-Rabelais
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- n-3 long-chain polyunsaturated fatty acids, docosahexaenoic acid, eicosapentaenoic acid, docetaxel, breast cancer, microvascularization, contrast-enhanced ultrasound, epiregulin, amphiregulin, angiogenesis, chemosensitization, dietary fatty acids
- MeSH terms
- Docetaxel, Animals, Diet, Docosahexaenoic Acids, Fatty Acids, Female, Neovascularization, Pathologic, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Mammary Neoplasms, Animal, Rats, Sprague-Dawley, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.